Ansell shares surge 6% on AGM and trading update

Ansell shares are up after management raised earnings guidance for the year.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Earnings upgrade: FY26 adjusted EPS lifted to US$1.37 to US$1.49, up from US$1.33 to US$1.45, after stronger-than-expected first-quarter trading.
  • Tariffs managed: Ansell is offsetting higher US tariffs through price increases and reduced sourcing from China, thereby protecting profits.
  • Efficiency gains: The company’s productivity program has delivered $47 million in savings, with synergies from the KBU acquisition ahead of plan.

Shares in Ansell Ltd (ASX: ANN) surged on Tuesday after the personal protective equipment manufacturer delivered a better-than-expected trading update and raised its earnings outlook at its 2025 Annual General Meeting.

At the time of writing, the Ansell share price is up 6% to $36.48, with the market reacting strongly after the company raised its guidance.

Health professional putting on gloves.

Image source: Getty Images

Trading update

Management now expects FY26 adjusted earnings per share of US$1.37 to US$1.49, up from the previously provided range of US$1.33 to US$1.45.

The upgrade follows a solid start to the financial year for Ansell, with management reporting sales and margins tracking ahead of plan, buoyed by favourable foreign-exchange trends, lower freight costs, synergy gains from its Kimberly-Clark PPE business acquisition, and ongoing manufacturing productivity improvements

Whilst US tariffs have been a hot topic this year, Ansell has found ways to manage this shift by increasing its prices and reducing its sourcing from China, which faces higher US tariffs. Management's goal is to fully offset the impact of the tariffs through a range of measures designed to protect the bottom line.

Ansell also reported solid productivity gains as its Accelerated Productivity Investment Program (APIP) continues to deliver results. The program has generated $47 million in cost savings so far in FY25, and management is targeting $50 million in cost savings for FY26. The company is also investing in a new enterprise resource planning (ERP) system to streamline operations and unlock digital efficiencies.

The integration of Kimberly-Clark's PPE business (KBU) (Ansell's largest-ever acquisition) was completed ahead of schedule, achieving $5 million in cost synergies and prompting a lift in its FY27 synergy target from $10 million to $15 million.

Ansell also reaffirmed its $200 million on-market share buyback, with $29 million completed so far this year to date.

Foolish bottom line

After a few years of losing ground following the COVID pandemic hype, Ansell is a business that is finally finding its footing. Favourable exchange rates may have contributed to this positive trading update, but this is more than just luck.

The company is creating its own luck through disciplined price increases and operational efficiency gains. With tariff risks under control, synergies running ahead of plan, and earnings guidance upgraded, Ansell's 6% share price jump is earned.

Ansell shares are now up 30% from their tariffs-related lows from earlier this year, and investor confidence is growing once again. It looks like full steam ahead for Ansell.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »